Literature DB >> 21562827

Developing consensus 3D-QSAR and pharmacophore models for several beta-secretase, farnesyl transferase and histone deacetylase inhibitors.

Hsin-Yuan Wei1, Guan-Ju Chen, Chih-Lun Chen, Thy-Hou Lin.   

Abstract

Three consensus 3D-QSAR (c-3D-QSAR) models were built for 38, 34, and 78 inhibitors of β-secretase, histone deacetylase, and farnesyltransferase, respectively. To build an individual 3D-QSAR model, the structures of an inhibitor series are aligned through docking of a protein receptor into the active site using the program GOLD. CoMFA, CoMSIA, and Catalyst are then performed for the training set of each structurally aligned inhibitor series to obtain a 3D-QSAR model. Since the consensus in features identified is high for the same pharmacophore features selected for building a 3D-QSAR model by a 3D-QSAR method, a c-3D-QSAR model for each inhibitor series is constructed by combining the pharmacophore features selected for building the 3D-QSAR model using the SYBYL spread sheet and PLS module. Each c-3D-QSAR pharmacophore model built was examined visually and compared with that obtained by simultaneous mapping of the corresponding 3D-QSAR pharmacophores built onto a selected inhibitor structure. It was found that the c-3D-QSAR model built for an inhibitor series improves not only the overall prediction statistics for both training and test sets but also the prediction accuracy for some less active inhibitors of the series.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21562827     DOI: 10.1007/s00894-011-1094-4

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  56 in total

1.  Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation.

Authors:  Araz Jakalian; David B Jack; Christopher I Bayly
Journal:  J Comput Chem       Date:  2002-12       Impact factor: 3.376

2.  Quantitative structure-activity relationship study of histone deacetylase inhibitors.

Authors:  Aihua Xie; Chenzhong Liao; Zhibin Li; Zhiqiang Ning; Weiming Hu; Xianping Lu; Leming Shi; Jiaju Zhou
Journal:  Curr Med Chem Anticancer Agents       Date:  2004-05

3.  Modeling ligand-receptor interaction for some MHC class II HLA-DR4 peptide mimetic inhibitors using several molecular docking and 3D QSAR techniques.

Authors:  Hsin-Yuan Wei; Keng-Chang Tsai; Thy-Hou Lin
Journal:  J Chem Inf Model       Date:  2005 Sep-Oct       Impact factor: 4.956

4.  Vorinostat.

Authors:  Steven Grant; Chris Easley; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2007-01       Impact factor: 84.694

Review 5.  Ras farnesyltransferase: a new therapeutic target.

Authors:  D M Leonard
Journal:  J Med Chem       Date:  1997-09-12       Impact factor: 7.446

6.  Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity.

Authors:  G Klebe; U Abraham; T Mietzner
Journal:  J Med Chem       Date:  1994-11-25       Impact factor: 7.446

Review 7.  Histone deacetylases (HDACs): characterization of the classical HDAC family.

Authors:  Annemieke J M de Ruijter; Albert H van Gennip; Huib N Caron; Stephan Kemp; André B P van Kuilenburg
Journal:  Biochem J       Date:  2003-03-15       Impact factor: 3.857

8.  A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.

Authors:  V M Richon; S Emiliani; E Verdin; Y Webb; R Breslow; R A Rifkind; P A Marks
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-17       Impact factor: 11.205

Review 9.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

10.  Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101.

Authors:  Jane A Plumb; Paul W Finn; Robert J Williams; Morwenna J Bandara; M Rosario Romero; Claire J Watkins; Nicholas B La Thangue; Robert Brown
Journal:  Mol Cancer Ther       Date:  2003-08       Impact factor: 6.261

View more
  1 in total

1.  Exploring the binding of BACE-1 inhibitors using comparative binding energy analysis (COMBINE).

Authors:  Shu Liu; Rao Fu; Xiao Cheng; Sheng-Ping Chen; Li-Hua Zhou
Journal:  BMC Struct Biol       Date:  2012-08-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.